-
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical…
24 Apr 2024 20:02 GMT
… metastatic castration resistant prostate cancer have been … with metastatic castration resistant prostate cancer (mCRPC).
Presenter: … metastatic castration-resistant prostate cancer and other tumor … metastatic castration-resistant prostate cancer. This program …
-
Masturbation can lower prostate cancer risk: expert
24 Apr 2024 19:40 GMT
… frequently might keep prostate cancer at bay. Prostate cancer is the second … that ejaculation can reduce prostate cancer by decreasing the … a heightened risk of prostate cancer.
Men with lower … between ejaculation frequency and prostate cancer is not fully …
-
Hartford HealthCare unveils latest in robotic innovation for prostate cancer care
24 Apr 2024 18:14 GMT
… changer for the treatment of prostate cancer.
Hartford HealthCare’s Tallwood Urology … latest in robotic innovation for prostate cancer care- high-frequency ultrasounds.
The …
-
The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
24 Apr 2024 14:58 GMT
Prostate cancer is a common malignancy driven … , the development of castration-resistant prostate cancer (CRPC) poses a significant challenge … genetically engineered mouse models with prostate tumors at different stages. They revealed …
-
European Commission approves Astellas’ drug for expanded prostate cancer Treatment
24 Apr 2024 14:24 GMT
… for advanced prostate cancer.
“Many men with hormone-sensitive prostate cancer undergo arduous … and early death.”
Potential new prostate cancer treatment
Ahsan Arozullah, senior … the early, recurrent hormone-sensitive prostate cancer setting. Astellas is in …
-
Masturbating might slash risk of prostate cancer, claims expert (and more is better!)
24 Apr 2024 12:48 GMT
… ejaculating may help protect against prostate cancer.
Dr Kelly wrote: … ejaculation can reduce prostate cancer by decreasing the … ejaculation frequency and prostate cancer is not fully … quickly does it develop?
Prostate cancer usually develops slowly, so …
-
EC approves Astellas’ Xtandi for high-risk prostate cancer treatment
24 Apr 2024 11:23 GMT
… (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are not suitable … the early, recurrent hormone-sensitive prostate cancer setting. Astellas is in active … with non-metastatic castration-sensitive prostate cancer with BCR at high risk …
-
Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.
24 Apr 2024 08:24 GMT
… of active surveillance (AS) for prostate cancer is increasing, and racial disparities … low- and favorable intermediate-risk prostate cancer, with particular focus on the … low- or favorable intermediate-risk prostate cancer. The odds of receiving AS …
-
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
24 Apr 2024 08:24 GMT
… of patients with castrate-resistant prostate cancer at high risk of developing …
-
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
24 Apr 2024 08:24 GMT
… of some men with advanced prostate cancer. Rare but serious side … AML, is incompletely understood in prostate cancer. We hypothesized that PARP inhibitors … prospectively enrolled participants with advanced prostate cancer treated with PARP inhibitors. The …